176 related articles for article (PubMed ID: 33749497)
21. Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation.
Major-Monfried H; Hosszu K; McAvoy DP; Vallone A; Shukla N; Gillio A; Spitzer B; Kung AL; Cancio M; Curran K; Scaradavou A; Oved JH; O'Reilly RJ; Boelens JJ; Harris AC
Cytotherapy; 2024 May; 26(5):466-471. PubMed ID: 38430078
[TBL] [Abstract][Full Text] [Related]
22. [A clinical study of allogeneic hematopoietic stem cell transplantation in 23 patients with early T-cell precursor acute lymphoblastic leukemia].
Zhu YX; Zhu MQ; Dai HP; Liu SN; Yin J; Li Z; Cui QY; Zhu XM; Wu DP; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1021-1025. PubMed ID: 32023734
[No Abstract] [Full Text] [Related]
23. Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia.
Baek DW; Lee JM; Kim J; Cho HJ; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Aug; 14(8):765-775. PubMed ID: 34313508
[TBL] [Abstract][Full Text] [Related]
24. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
25. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
26. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Zhang X; Li J; Jin J; Yu W
Ann Hematol; 2020 Feb; 99(2):395-397. PubMed ID: 31879788
[No Abstract] [Full Text] [Related]
27. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
28. Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia?
Mirgh S; Ahmed R; Agrawal N; Khushoo V; Garg A; Francis S; Tejwani N; Singh N; Bhurani D
Br J Haematol; 2019 Oct; 187(2):e33-e35. PubMed ID: 31452197
[No Abstract] [Full Text] [Related]
29. Early T-Cell Precursor Acute Lymphoblastic Leukemia and T/Myeloid Mixed Phenotype Acute Leukemia Possess Overlapping Characteristics and Both Benefit From CAG-Like Regimens and Allogeneic Hematopoietic Stem Cell Transplantation.
Liu S; Cui Q; Dai H; Song B; Cui W; Xue S; Qiu H; Miao M; Jin Z; Li C; Fu C; Wang Y; Sun A; Chen S; Zhu X; Wu D; Tang X
Transplant Cell Ther; 2021 Jun; 27(6):481.e1-481.e7. PubMed ID: 33785365
[TBL] [Abstract][Full Text] [Related]
30. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant.
Begna KH; Abdallah NH; Janania-Martinez M; Mangaonkar AA; Rangan A; Herrick JL; Gangat N
Haematologica; 2024 Feb; 109(2):689-692. PubMed ID: 37706335
[No Abstract] [Full Text] [Related]
32. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
[TBL] [Abstract][Full Text] [Related]
33. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
[TBL] [Abstract][Full Text] [Related]
34. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
Malone A; Smith OP
Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
[No Abstract] [Full Text] [Related]
35. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
36. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia.
Ghara N; Saha V
Lancet Haematol; 2023 Jun; 10(6):e391-e393. PubMed ID: 37167993
[No Abstract] [Full Text] [Related]
37. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
[No Abstract] [Full Text] [Related]
38. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
[TBL] [Abstract][Full Text] [Related]
39. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
[TBL] [Abstract][Full Text] [Related]
40. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
